How important is intestinal cytochrome P450 3A metabolism?

Trends in Pharmacological Sciences

Volumn 30, Issue 5, 2009, Pages 223-227

  van Herwaarden, Antonius E ^a   van Waterschoot, Robert A B ^a   Schinkel, Alfred H ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; COMPLEMENTARY DNA; CYCLOSPORIN; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; DOCETAXEL; ERYTHROMYCIN; FELODIPINE; MIDAZOLAM; XENOBIOTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CYP3A GENE; DRUG ABSORPTION; DRUG ELIMINATION; DRUG UPTAKE; ENZYME LOCALIZATION; ENZYME METABOLISM; FIRST PASS EFFECT; GRAPEFRUIT JUICE; IN VIVO STUDY; INTESTINE ABSORPTION; INTESTINE EPITHELIUM; KNOCKOUT GENE; KNOCKOUT MOUSE; LIVER; LIVER METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CYTOCHROME P-450 CYP3A; HUMANS; INTESTINES; LIVER; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MODELS, BIOLOGICAL; P-GLYCOPROTEIN;

EID: 65349115966     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2009.02.003     Document Type: Article

References (25)

1. Guengerich F.P. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol. 39 (1999) 1-17
2. Lamba J.K., et al. Genetic contribution to variable human CYP3A mediated metabolism. Adv. Drug Deliv. Rev. 54 (2002) 1271-1294
3. Dresser G.K., et al. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin. Pharmacokinet. 38 (2000) 41-57
4. Willson T.M., and Kliewer S.A. PXR, CAR and drug metabolism. Nat. Rev. Drug Discov. 1 (2002) 259-266
5. Mandlekar S., et al. Modulation of metabolic enzymes by dietary phytochemicals: a review of mechanisms underlying beneficial versus unfavorable effects. Curr. Drug Metab. 7 (2006) 661-675
6. Kuehl P., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP34A5 expression. Nat. Genet. 27 (2001) 383-391
7. Koch I., et al. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab. Dispos. 30 (2002) 1108-1114
8. Lin Y.S., et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol. Pharmacol. 62 (2002) 162-172
9. Lin J.H., et al. Is the role of the small intestine in first-pass metabolism overemphasized?. Pharmacol. Rev. 51 (1999) 135-156
10. Lown K.S., et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Drug Metab. Dispos. 22 (1994) 947-955
11. Gorski J.C., et al. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin. Pharmacol. Ther. 74 (2003) 275-287
12. Von Richter O., et al. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin. Pharmacol. Ther. 75 (2004) 172-183
13. Mouly S.J. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. Clin. Pharmacol. Ther. 78 (2005) 605-618
14. Hall S.D., et al. Molecular and physical mechanisms of first-pass extraction. Drug Metab. Dispos. 27 (1999) 161-166
15. Lown K.S., et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J. Clin. Invest. 99 (1997) 2545-2553
16. Kolars J.C., et al. First-pass metabolism of cyclosporin by the gut. Lancet 338 (1991) 1488-1490
17. Paine M.F., et al. First pass metabolism of midazolam by the human intestine. Clin. Pharmacol. Ther. 60 (1996) 14-24
18. Wu C.-Y., et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin. Pharmacol. Ther. 58 (1995) 492-497
19. van Herwaarden A.E., et al. Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J. Clin. Invest. 117 (2007) 3583-3592
20. van Herwaarden A.E., et al. Midazolam and cyclosporin A metabolism in transgenic mice with liver-specific expression of human CYP3A4. Drug Metab. Dispos. 33 (2005) 892-895
21. Bardelmeijer H.A., et al. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res. 62 (2002) 6158-6164
22. van Waterschoot R.A., et al. Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes. Mol. Pharmacol. 73 (2008) 1029-1036
23. Schinkel A.H., and Jonker J.W. Mammalian drug efflux transporters of the ATP-binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev. 55 (2003) 3-29
24. Benet L.Z., and Cummins C.L. The drug efflux-metabolism alliance: biochemical aspects. Adv. Drug Deliv. Rev. 50 (2001) S3-S11
25. Cummins C.L., et al. In vivo modulation of intestinal Cyp3a metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model. J. Pharmacol. Exp. Ther. 305 (2003) 306-314